Overview

Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

Status:
Recruiting

Trial end date:
2021-01-01

Target enrollment:

Participant gender:

Summary

A Phase Ib, Open-label, Single-center study to assess the safety of cancer-immunotherapy induction with Tremelimumab and Durvalumab prior to Chemoradiotherapy in the treatment of locally advanced NSCLC.

Phase:

Phase 1

Details

Lead Sponsor:

The Netherlands Cancer Institute

Collaborator:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Durvalumab
Pemetrexed
Tremelimumab